ABSTRACT: Introduction: The p.A1156T mutation alters the function of the voltage-gated sodium channel Nav1.4 on the muscle sarcolemma, causing a channelopathy without overt myotonia or periodic paralysis but with myalgic pain. Methods: A postal survey was conducted to assess the prevalence and characteristics of pain and related symptoms in individuals with the p.A1156T mutation. A specific questionnaire, intensity and interference subscales of the Brief Pain Inventory, pain drawing, Widespread Pain Index, quality of life (RAND-36), and the Beck Depression Inventory were completed. Results: Twenty of 24 patients replied. Current pain was reported by 16 respondents; the other 4 had experienced pain previously. Most commonly, pain was widespread and exercise-induced. The severity and the impact of pain on daily life were considerable, although varied. Discussion: This sodium channelopathy is another entity in the growing number of diseases causing widespread myalgic pain that resembles the pain seen in fibromyalgia syndrome.
A nucleotide change c.3466G>A in exon 19 of the SCN4A causes the amino acid change p.A1156T in domain III of the alpha subunit of the voltagegated sodium channel Nav1. 4 . 5, 6 The alpha subunit, coded by the gene SCN4A located at chromosome 17q23-25, facilitates ion transport through the cell membrane.
The p.A1156T mutation has been described in 1 Finnish family and 2 South Korean patients who shared features of hyperkalemic periodic paralysis and paramyotonia congenita. 5, 6 We recently reported a series of 30 new patients with this mutation, and described the clinical consequences of this mutation. These patients presented with widespread pain, muscular stiffness, and exercise and cold-induced cramps, but without signs of clinical myotonia, paramyotonia, or periodic paralyses. 7 According to the ExAC database, the frequency of the p.A1156T mutation in the Finnish population is 60 in 100,000, meaning that there are more than 3,000 mutation carriers and (due to the adult onset of symptoms) approximately 1,000 affected individuals in Finland. 7 Muscular pain is a frequent symptom in nondystrophic myotonias, as reported by approximately 80% of these patients. 8, 9 The severity of symptoms of SCN4A-related myotonias can vary from very mild ones producing minimal or no interference with daily life to ones that have a severe impact. 9 The aim of this postal survey was to assess the prevalence, characteristics, and severity of pain, muscular, and depressive symptoms, and quality of life (QoL) in patients with the p.A1156T mutationassociated sodium channelopathy.
METHODS
A postal survey was conducted in the spring of 2016. The study was approved by the local ethics committee and all participants gave written informed consent. The reporting of this study conforms to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement. 10 Participants. The study population consisted of all traceable Finnish patients with p.A1156T mutation-associated sodium channelopathy, in whom the diagnosis had been verified by molecular genetic methods through the spring of 2016 (n 5 29). 7 One patient was excluded due to cognitive impairment, 1 patient was less than 18 years old, and 3 patients could not be contacted by mail. Hence, 24 individuals were asked to participate in the survey. 13 ; and (4) the Finnish modification of the short form of the Beck Depression Inventory. 14 Sociodemographic background, the occurrence of muscular pain, headache and gastrointestinal symptoms, nonpainful muscular symptoms (unpleasant muscular sensations, weakness, stiffness, and difficulties in initiating or controlling movements), factors alleviating and exacerbating pain, and current pain medication were assessed. Designed for the purpose of this study, a numerical rating scale (NRS) of 0-10 (0 5 "no symptoms" to 10 5 "the worst possible intensity of the symptom") and multiple-choice and open questions were used in the assessment. If applicable, an NRS score of 4 was chosen as the lower limit for moderate symptom intensity, as it is most commonly accepted for clinical use. 15 We used a similar approach in a previous survey of pain in myotonic dystrophy type 2. 16 Finnish language copies of this questionnaire are available from the author upon request. Refer to Supplementary Material (available online) for further details.
Questionnaires
Statistical Analysis. Descriptive statistics, including median and the first and third quartiles (i.e., interquartile range, IQR), were calculated using IBM SPSS Statistics for Macintosh version 24 (IBM SPSS Corp., Armonk, New York). We used the onesample t-test for statistical comparison of mean QoL values between the study sample and the general population. Because the population values were expressed as means, a one-sample ttest was used for this purpose, although RAND-36 subscales rarely conform to a normal distribution. 17 The a-level was set at 0.05 for all tests. No adjustment was made for multiple testing.
RESULTS
The response rate was 20 of 24 (83%). Table 1 shows demographic and clinical characteristics of the respondents. Pain was located over the limbs or trunk in 15 of 20 respondents (Fig. 1) . In 8 of 20 drawings, pain was bilaterally symmetric in all 21 defined areas. Median WPI was 8.5 (IQR 5-11.75), and WPI 7 was reported by 14 of 20 respondents. Pain intensity was highest in the areas of low back and lower limbs (median pain intensity for both was 6 on the NRS). Pain increased with exercise in 78% and cold in 50% of patients, whereas pain was relieved by rest in 83% and warmth in 61%. Most respondents (16 of 20) reported multiple types of pain.
Unpleasant muscular sensations, muscle weakness, stiffness, and difficulties in initiating or controlling movements with intensity of NRS 4 were reported by 15 (75%), 13 (65%), 15 (75%), and 14 (70%) respondents, respectively. Headache occurring several days per week was reported by 6 of 20 respondents.
Pain medication, most commonly nonsteroidal anti-inflammatory drugs (n 5 12) and paracetamol (acetaminophen) (n 5 8), was used on a weekly or daily basis by 14 of 20 (70%) respondents. Other analgesics were pregabalin (n 5 2), codeine (n 5 1), tramadol (n 5 1), oxycodone (n 5 1), and amitriptyline (n 5 1). The assessed median efficacy of current pain medication was 6 (IQR 4-8) on the NRS.
Pain interference was highest for general activity (median 4.5, IQR 2-6.75 on the NRS) and normal work (median 4, IQR 3-7 on the NRS). Insomnia was reported by 8 responders. RAND-36 QoL scores (Table 2) on the emotional and social domains were higher than the scores on the physical domains.
DISCUSSION
Exercise-and cold-induced, widespread pain was common in our cohort of patients. All respondents had pain during their course of illness. The severity and the impact of pain on daily life were variable. In this population, 27% were incapacitated for work, as compared with 6.4% of the Finnish general population. 18 Pain interference was highest in the domains of general activity and normal work.
Half of the respondents reported pain less often than weekly. QoL subscales related to emotional well-being, emotional role functioning, and social functioning were preserved, and severe depressive symptoms were rare. In this cohort of patients with a p.A1156T mutation, muscular symptoms dominated and other organ systems or mental health were much less affected. This is different than in myotonic dystrophy type 2 (DM2), 16 in which pain was clearly associated with depressive symptoms and reduced emotional and social QoL. Also, in a previous cohort of patients with different SCN4A mutations (but not including p.A1156T) and DM2, QoL scores were higher in the SCN4 mutation group than in the DM2 group. 9 The exact mechanisms of pain in SCN4A mutation-associated channelopathies are not fully understood. Most SCN4A mutations cause gain-of-function defects, either disrupted inactivation or enhanced activation. 4 Mildly attenuated fast inactivation by the p.A1156T channel, demonstrated by functional studies, does not cause clinical myotonia or paramyotonia, although myotonic discharges have been detected by electromyography (EMG) in most such patients. 7 Pain has been reported in various proportions of myotonia patients with different SCN4A mutations. 9, 19, 20 Patients with certain muscular disorders, such as DM2 and myotonia congenita, can present with chronic widespread pain, which may be indistinguishable from fibromyalgia. [21] [22] [23] There is evidence that EMG abnormalities in patients with myalgia can differentiate an underlying channelopathy from nonspecific myalgic syndromes. 24 In our patients with the p.A1156T mutation, initial EMG studies showed either myotonic discharges or increased insertional activity, as described previously. 7 Diagnostic evaluations of nonmyotonic dystrophies and many other genetic muscular syndromes can be challenging. 9 The identification of a specific diagnosis underlying chronic widespread pain is important for avoiding wrong diagnoses, for precise nomenclature in daily practice, and for future research on targeted pathophysiology and treatment. Multimodal and deconstructive strategies, such as the Research Domain Criteria (RDoC) framework, could help to integrate novel data on the research into the nature of complex phenomena, including fibromyalgia and chronic pain. 25, 26 There are several limitations to our study. The cross-sectional setting does not permit causal interpretations on the mechanisms of pain. The setting is also prone to recall bias. Both validated and customized instruments were used in this survey, which may have influenced the comparability of some of our results with previous research.
In conclusion, this channelopathy is another entity among the growing number of diseases causing widespread myalgic pain that resembles the pain of fibromyalgia syndrome.
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